AlloVir, Inc. (NASDAQ:ALVR – Get Free Report) shares traded down 2.5% during trading on Thursday . The company traded as low as $4.4750 and last traded at $4.71. 64,589 shares changed hands during trading, an increase of 312% from the average session volume of 15,685 shares. The stock had previously closed at $4.83.
AlloVir Price Performance
The stock has a fifty day moving average of $4.72 and a 200 day moving average of $7.07. The firm has a market capitalization of $22.39 million, a P/E ratio of -0.22 and a beta of 0.63.
About AlloVir
AlloVir, Inc is a clinical-stage biopharmaceutical company specializing in the development of off-the-shelf, allogeneic virus-specific T-cell immunotherapies for the prevention and treatment of life-threatening viral infections in immunocompromised patients. The company’s proprietary Multi-Virus-Targeting Cell (MTC) platform enables the rapid identification, isolation and expansion of virus-specific T cells from healthy donors, with the aim of offering broad coverage against multiple clinically significant viruses.
AlloVir’s pipeline includes several product candidates designed to address unmet needs in transplant medicine and other immunosuppressed settings.
Further Reading
- Five stocks we like better than AlloVir
- Starbucks Builds Sovereign AI to Cut $400 Million in Software Costs
- Power Struggle: Wolfspeed Sues Navitas Over AI Chips
- Why WD-40 Is Proving Great Businesses Never Go Out of Style
- Pushing the Edge: Super Micro Computer Reboots the AI Landscape
Receive News & Ratings for AlloVir Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AlloVir and related companies with MarketBeat.com's FREE daily email newsletter.
